Samuel F. Hunter, MD, PhD
from Neurology Reviews
An open-label study indicates that patients with multiple sclerosis may benefit from switching to alemtuzumab.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Neurology Reviews?
This episode is 8 minutes long.
When was this Neurology Reviews episode published?
This episode was published on September 28, 2018.
Can I download this Neurology Reviews episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.